Facilities

© GettyImages/acilo

Kite secures third approved cell therapy indication in Europe

By Jane Byrne

The European Commission (EC) has approved Kite’s CAR T-cell therapy, Yescarta, (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after three or more lines of systemic therapy.

Pic:getty/omersukrugoksu

Lilly invests $2.1bn in new Indiana manufacturing sites

By Rachel Arthur

Eli Lilly and Company plans to expand its manufacturing footprint in Indiana by investing $2.1bn in two new manufacturing sites at Indiana's LEAP Lebanon Innovation and Research District in Boone County.

Pic:getty/chaluk

Matica Bio opens new Texas cell and gene therapy facility

By Rachel Arthur

CDMO Matica Bio has opened a new 45,000-square-foot facility dedicated to the production of viral vectors and cell-based products used in cell and gene therapies, vaccines, oncolytic therapies and other genetic medicines.

Pic:getty/maxiphoto

Catalent buys UK vaccine manufacturing centre

By Rachel Arthur

US company Catalent is acquiring the UK’s Vaccine Manufacturing and Innovation Centre in Harwell: a facility which had been planned to support COVID-19 and wider vaccine production and which is still under construction.

© GettyImages/Design Cells

Milestone approval for Kite CAR-T cell therapy

By Jane Byrne

The US FDA has approved Yescarta, Kite's CAR-T cell therapy, for initial treatment in adults with large B-cell lymphoma (LBCL) that is refractory to one prior therapy or that relapses within 12 months of first-line chemoimmunotherapy.

© GettyImages/Cecilie_Arcurs

Novartis inks contract manufacturing deal with Carisma

By Jane Byrne

Novartis continues down the third-party manufacturing route, as it secures an agreement with Carisma Therapeutics, a firm developing a cell therapy platform focused on engineered macrophage-based therapeutics.

pic:getty/zulotukhin

Flow Eighteen38 to double protein purification capacity

By Rachel Arthur

Flow Eighteen38, a protein sciences division created to facilitate and accelerate antibody characterization and protein purification projects, has announced a €5m ($5.58m) investment into its protein production and biophysical characterization capabilities...

Pic:getty/naruedom

Moderna to build mRNA manufacturing site in Kenya

By Rachel Arthur

mRNA pioneer Moderna has entered into a Memorandum of Understanding with the Government of the Republic of Kenya to establish an mRNA manufacturing facility in the country.